Literature DB >> 9748610

Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies.

S Bunge1, P R Clements, S Byers, W J Kleijer, D A Brooks, J J Hopwood.   

Abstract

Fibroblasts from 16 patients with known alpha-L-iduronidase gene mutations and different clinical phenotypes of mucopolysaccharidosis type I (MPS I) were investigated in order to establish genotype/phenotype correlations. Enzyme kinetic studies were performed using the specific alpha-L-iduronidase substrate iduronosyl anhydro[1-3H]mannitol-6-sulfate. Specific residual enzyme activities were estimated using the kinetic parameters and an immunoquantification assay which determines levels of alpha-L-iduronidase protein. Cells were cultured in the presence of [35S]sulfate and the in vivo degradation of accumulated labelled glycosaminoglycans measured after different chase times. Residual enzyme activity and different amounts of residual enzyme protein were present in extracts from 9 of 16 cell lines covering a wide spectrum of clinical severity. Catalytic capacity, calculated as the product of kcat/Km and ng iduronidase protein per mg cell protein, was shown in most cases to be directly related to the severity of clinical phenotype, with up to 7% of normal values for patients with the attenuated form of MPS I (Scheie) and less than 0.13% for severely affected patients (Hurler) In vitro turnover studies allowed further refinement of correlations between genotype and phenotype. Scheie disease compared to Hurler disease patients were shown to accumulate smaller amounts of glycosaminoglycans that were also turned over faster. A combination of turnover and residual enzyme data established a correlation between the genotype, the biochemical phenotype and the clinical course of this lysosomal storage disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748610     DOI: 10.1016/s0925-4439(98)00046-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  30 in total

1.  Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly.

Authors:  A Hinek; S E Wilson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 2.  Is genotype determination useful in predicting the clinical phenotype in lysosomal storage diseases?

Authors:  I Maire
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 3.  Variable clinical presentation in lysosomal storage disorders.

Authors:  M Beck
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

4.  Mutations in POMGNT1 cause non-syndromic retinitis pigmentosa.

Authors:  Mingchu Xu; Takeyuki Yamada; Zixi Sun; Aiden Eblimit; Irma Lopez; Feng Wang; Hiroshi Manya; Shan Xu; Li Zhao; Yumei Li; Adva Kimchi; Dror Sharon; Ruifang Sui; Tamao Endo; Robert K Koenekoop; Rui Chen
Journal:  Hum Mol Genet       Date:  2016-01-28       Impact factor: 6.150

5.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

6.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.

Authors:  Dan Wang; Valery Belakhov; Jeyakumar Kandasamy; Timor Baasov; Su-Chen Li; Yu-Teh Li; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2011-10-19       Impact factor: 4.797

7.  Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.

Authors:  Ashley D Dierenfeld; Michael F McEntee; Carole A Vogler; Charles H Vite; Agnes H Chen; Merry Passage; Steven Le; Sahil Shah; Jackie K Jens; Elizabeth M Snella; Karen L Kline; Jennifer D Parkes; Wendy A Ware; Lori E Moran; Amanda J Fales-Williams; Jane A Wengert; R David Whitley; Daniel M Betts; Amy M Boal; Elizabeth A Riedesel; William Gross; N Matthew Ellinwood; Patricia I Dickson
Journal:  Sci Transl Med       Date:  2010-12-01       Impact factor: 17.956

8.  Readthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease.

Authors:  B Pérez; P Rodríguez-Pombo; M Ugarte; L R Desviat
Journal:  Mol Syndromol       Date:  2012-10-02

Review 9.  Therapeutics based on stop codon readthrough.

Authors:  Kim M Keeling; Xiaojiao Xue; Gwen Gunn; David M Bedwell
Journal:  Annu Rev Genomics Hum Genet       Date:  2014-04-18       Impact factor: 8.929

Review 10.  Lysosomal storage disorders: emerging therapeutic options require early diagnosis.

Authors:  Peter J Meikle; John J Hopwood
Journal:  Eur J Pediatr       Date:  2003-11-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.